Over 200 interstitial lung diseases, from ultra rare to relatively common, are recognised.
Most interstitial lung diseases are characterised by inflammation or fibrosis within the …

Interstitial lung disease (ILD) secondary to drug-induced lung injury is an increasingly
common cause of morbidity and mortality. The number of drugs associated with the …

Objective We provide evidence‐based recommendations regarding the treatment of
interstitial lung disease (ILD) in adults with systemic autoimmune rheumatic diseases …

Objective Patients at high risk of rheumatoid arthritis–associated interstitial lung disease (RA‐
ILD) would benefit from being identified before the onset of respiratory symptoms; this can …

Background Interstitial lung disease (ILD) is a serious complication that represents the
second leading cause of death in patients with rheumatoid arthritis (RA). Treatment of RA …

Interstitial lung disease (ILD) is a frequent complication of rheumatoid arthritis (RA) that is
associated with a significant increase in mortality. Several risk factors for the development of …

Methotrexate is a key component of the treatment of inflammatory rheumatic diseases and
the mainstay of therapy in rheumatoid arthritis. Hepatotoxicity has long been a concern for …

Interstitial lung diseases (ILDs) other than idiopathic pulmonary fibrosis (IPF) have an array
of immunomodulatory treatment options compared with IPF, due to their inflammatory …

Importance Current data are lacking regarding the risk of biologic and targeted synthetic
disease-modifying antirheumatic drug (b/tsDMARD) use on the development of interstitial …

Background Rheumatoid arthritis (RA) sufferers have a higher mortality risk than the healthy
population, and methotrexate (MTX) as a base drug for RA treatment is believed to affect …